The Federal Reserve recently announced a 25-basis-point increase in its benchmark overnight lending rate, bringing it to a range of 3.75% to 4.00%. The market views this first rate hike in three years as the dawn of a new tightening cycle. Prominent financial commentators note that investing in equities under the current conditions is akin to sailing against the tide; investors are effectively taking on immense risks by betting against central bank policy, with each rate hike poised to exert direct downward pressure on stock prices.

Following the meeting, the Federal Reserve Chair reiterated the commitment to taming inflation, emphasizing that current price levels remain too high and have persisted for too long. This rate hike is aimed at driving inflation back down to the target level. Such concerns over price pressures have directly dampened market risk appetite. Consequently, the three major U.S. stock indices, which had earlier posted gains, all closed in the red following the policy announcement. The economically sensitive Dow Jones Industrial Average plunged 631 points, a drop of 1.2%, while the S&P 500 and the Nasdaq Composite also edged lower by 0.5% and 0.01%, respectively.

As borrowing costs climb, the high-interest-rate environment is not only dragging down real economic activity but also significantly boosting the allure of fixed-income assets. Currently, the yield on the 10-year U.S. Treasury note has breached the 5% threshold, approaching a two-decade high. This makes risk-free returns more attractive for portfolio allocation compared to equities, and the trend of capital shifting from risk assets to safe-haven assets is becoming increasingly pronounced.

In the face of the tightening cycle, some professional investors have not opted to completely liquidate their positions and exit the market. Instead, they have shifted their focus to a sharply narrowed universe of stock picks. Against the backdrop of broad sectoral pressure, capital is increasingly gravitating toward defensive assets capable of weathering the cycle, such as the healthcare and pharmaceutical sectors. With the potential for buying interest to return in the future, many sectors still struggle to outperform the broader market in the short term, leaving investors with a continuously shrinking pool of high-quality investment targets.